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ABSTRACT
Schizophrenia (SZ) is a debilitating condition wherein those afflicted experience positive
symptoms, including hallucinations and delusions, as well as negative symptoms,
including alterations of processing affecting cognition and social interactions. The
NMDA receptor hypofunction model of SZ asserts that a reduction in hippocampal
NMDA receptor input produces the pathology of this disorder, promoting excessive
frontocortical excitatory neurotransmission – particularly overstimulation of basal
forebrain cholinergic neurons – that ultimately impairs cognitive and sensorimotor
processes. Orexin-A (OxA), a neuropeptide principally involved in wakefulness and
appetitive behaviors, has been shown to demonstrate cognitive-enhancing qualities in
models of psychiatric and neurodegenerative illness. In the present study, the effects of
OxA on attentional performance were examined in a NMDA receptor antagonist model
of SZ. Male Fischer 344 Brown Norway F1 Hybrid rats (N = 12) received both
intraperitoneal injections of MK-801 and intranasal administration of OxA prior to
placement in a sustained attention task requiring differentiation between signal trials
(500, 100, and 25ms illumination of a central panel light) and non-signal trials (no light
illumination). Overall, it was shown that the highest dose of OxA exacerbated MK-801induced attentional deficits. While the small OxA concentration slightly protected against
impairments in the correct rejection of the signal and increased omission rates at the
low dose of MK-801, this excitatory neuromodulator was largely unable to improve
performance in the attention task. These findings suggest that, in a state of cortical
hyperexcitation like what is observed both in SZ and following NMDA receptor
antagonism, the introduction of pharmacotherapies augmenting activity at the
orexinergic system further exacerbates existing cognitive dysfunction in lieu of
alleviating these symptoms.
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Chapter 1: Introduction and Research Hypotheses
Overview
The debilitating and complex condition known as schizophrenia (SZ) is a
chronic disorder of the nervous system. As described in the fifth edition of the
Diagnostic and Statistical Manual of Mental Disorders (DSM-5), SZ is comprised
of five primary symptoms: delusions, hallucinations, muddled speech,
disorganized or catatonic behavior, and negative symptoms. Despite a low
incidence of diagnosis – with only 1% of the world’s population being affected at
a given time – those with SZ can experience a tremendously reduced quality of
life due to the severity of the symptoms (Faris & Dunham, 1939). The
experiences and behaviors associated with schizophrenia have historically been
dichotomized into “positive” and “negative” symptoms. Positive symptoms reflect
experiences or behaviors that should not normally be present. This class of
symptoms includes hallucinations, delusions, and disorganize thoughts and have
been classically treated using antipsychotic medications in tandem with
counseling. The severity of affective, cognitive, and social impairments – together
called negative symptoms because they denote a deficit in normal behaviors –
are notoriously difficult to ameliorate and are more strongly associated with poor
treatment outcomes than are the positive symptoms (Tamminga, Buchanan &
Gold, 1998). While classically categorized as negative symptoms, cognitive
impairments including attention, learning, and memory deficits are occasionally
organized separately from the positive and negative symptoms and are
considered their own distinct group (Bowie & Harvey, 2006). The Positive and
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Negative Syndrome Scale (PANSS), first described by Stanley Kay, Abraham
Fiszbein, and Lewis Opler in 1987, allows clinicians to measure the severity of
the two distinct categories of SZ symptoms in the context of the global
psychopathology.
Schizophrenia and the dopamine hypothesis
The pathology of SZ is a result of the dysregulation of multiple brain
networks, and parsing out the underlying neurological mechanisms inciting these
imbalances has been a challenge. For the last 50 years, the dopamine (DA)
hypothesis has provided informative insight into the investigation of the etiology
of the condition. The premise of this model proposes that the development and
symptoms of the disorder emerges from both subcortical hyperdopaminergia and
cortical hypodopaminergia (Howes & Kapur, 2009; Davis et al., 1991). Previous
findings have shown that there is an increase in expression and density of the
presynaptic dopamine-2 receptor (D2R) subtype, which enhances DA
neurotransmission upon stimulation, in extrastriatal regions of the SZ-afflicted
brain, including the substantia nigra, ventral putamen, and nucleus accumbens
(Wong et al., 1986; Joyce et al., 1988; Seeman & Kapur, 2000). Radioligand
binding and positron emission studies have also revealed a substantial loss of
cortical D1Rs in the prefrontal cortices of SZ patients, and the extent of the loss
is correlated to the severity of the cognitive impairment (Okubo et al., 1997; AbiDargham et al., 2002; Guo et al., 2003). Augmented DA activity in the striatum
and dampened DAergic neurotransmission in the cortex induces the positive and
negative symptomologies, respectively (Brozoski et al., 1979; Davis et al., 1991).

iv
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Both typical and atypical antipsychotics inhibit the activity of D2-like receptors in
the mesolimbic pathway, including the D2R as well as D3 and D4 receptor
subtypes (Kapur & Seeman, 2001; Burstein et al., 2005). In support of this
model, the degree to which a given neuroleptic occupies presynaptic D2Rs in
subcortical regions tends to predict its therapeutic efficacy (Seeman & Lee, 1975;
Creese, Burt & Snyder, 1976). Many second-generation antipsychotics assuage
DAergic hyperexcitation by antagonizing serotonin-2 receptors (5-HT2Rs) in
addition to D2Rs; by de-emphasizing their affinities to DA receptors and acting
more potently in in the 5-HTergic system, these drugs are able to alleviate SZ
symptoms with similar efficacy while minimizing extrapyramidal side effects
(Kuroki, Nagau & Nakahara, 2008; Leucht et al., 2009).
Despite having prevailed as the chief paradigm in the study of SZ of the
last several decades, the DA hypothesis does not encompass all facets of the
disorder; namely, there is not sufficient evidence to suggest that targeting DA
dysregulation effectually ameliorates the pathology in its entirety. While
antipsychotic medications tend to effectively normalize DA concentrations and
adequately assuage the severity of psychosis, they take several weeks to exert
their therapeutic effects while failing to improve the cognitive and social deficits
(Kapur et al., 2006). In addition to this, around 30 percent of those diagnosed are
classified as treatment-resistant, determined by little to no responsiveness to at
least two neuroleptics (Meltzer, 1997). Those who demonstrate a reduction in
positive symptomology resulting from antipsychotic therapy may still experience
the brunt of the negative syndrome. This inability of antipsychotic therapies
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primarily targeting DAergic neurons in reducing the catatonia, anhedonia,
and withdrawal associated with SZ necessitates the exploration of other major
neuromodulatory networks in its etiology and treatment.
N-methyl-D-aspartate receptors in SZ
In response to newly-available data as well as the widespread
shortcomings of the DA hypothesis, a new model centered around glutamatergic
dysregulation was posited. Following the discovery of markedly reduced Nmethyl-D-aspartate receptor (NMDAR) signaling in individuals with SZ by Kim
and colleagues in 1980, and later supported by findings demonstrating reduced
NR1 subunit mRNA in postmortem hippocampal tissue from SZ-afflicted
individuals when compared to healthy controls, an alternate hypothesis emerged
that attempted to incorporate this network into understanding the origins of the
widespread corticolimbic neurotransmitter imbalances (Gao et al., 2000; Clinton
& Meador-Woodruff, 2004). This model suggests that schizophrenic
symptomology is a byproduct of an underactive NMDAR system, disabling the
excitatory-inhibitory feedback loop and inciting extensive aberrations in glutamate
release. NMDAR hypofunction also disrupts other neurotransmitter systems,
particularly DAergic, 5-HTergic, and cholinergic networks (Kapur & Seeman,
2002). In large part, this NMDAR hypofunction model attempts to offer an
alternative to the typical neuroleptic medications that fail to remedy the cognitive,
social, and affective deficits. The NMDA hypofunction model suggests that
therapeutics targeting the glutamatergic system, which may also normalize DA
levels, could further improve treatment outcomes for these individuals.

iv
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NMDARs are iontropic glutamate receptors (iGluRs) that are expressed in
numerous brain regions, including the neocortex, ventral striatum, hippocampus,
amygdala, and, to a lesser extent, the thalamus (Meador-Woodruff & Healy,
2000). Glutamate, being the primary endogenous ligand that depolarizes these
receptors, is the main excitatory neurotransmitter in the brain and facilitates the
majority of all excitatory neurotransmission in the mammalian nervous system
(Traynelis et al., 2010). NMDARs themselves are either di- or tri-heteromeric in
nature, being comprised of an NR1 subunit – to which glutamate has an affinity –
as well as an NR2 glutamate-binding subunit and/or an NR3 glycine-binding
subunit (Schüler et al., 2008). With cell bodies originating in the ventral
hippocampus, the glutamatergic system is composed of NMDARs as well as αamino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors (AMPARs),
kainate receptors, and eight metabotropic glutamate receptor (mGluR) subtypes
(Nakanishi, 1992; Ferraguti & Shigemoto, 2006). The stimulation of these
glutamatergic receptor subtypes incites excitatory post-synaptic potentials
(EPSPs) and is vital for mediating various aspects of neural plasticity and
cognition (Li & Tsien, 2009). In particular, the CA1 region of the hippocampus is
densely packed with NMDARs and is necessary for long-term potentiation (LTP),
the synapse-strengthening process by which a wide array of cognitive processes
are facilitated (Collingridge & Bliss, 1987).
In general, the suppression of hippocampal NMDAR signaling significantly
reduces synaptic plasticity, producing cognitive deficits ranging from attentional
processing to long-term memory storage in both human and non-human
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paradigms (Tsien, Huerta & Tonegawa, 1996). Interestingly, the blockade of
NMDA receptors induces a state of cortical hyperexcitation. NMDAR
hypofunction boosts the extracellular release of endogenous excitatory
neurotransmitters, including glutamate and aspartate, which greatly augment the
stimulation of post-synaptic non-NMDA glutamatergic receptors, particularly in
the prefrontal cortex (PFC) (Moghaddam & Javitt, 2011). This general
hyperexcitation, in turn, diminishes the signal-to-noise ratio in cortical regions
associated with cognition (Bustos et al., 1992; Liu & Moghaddam, 1995;
Moghaddam et al., 1997). This conclusion has been supported by research
suggesting that there is an increased quantity of cortical glycine-binding sites
resulting from impaired glutamate neurotransmission in the brains of SZ patients
(Ishimaru, Kurumaji & Toru, 1992; Ishimaru, Kurumaji & Toru, 1994). As a
consequence of the overstimulation of non-NMDA glutamate receptors, the
release of other excitatory monoamines – particularly dopamine (DA) and
serotonin (5-HT) – is greatly augmented in the PFC and, to a lesser extent, the
striatum. Therefore, excessive glutamatergic activity increases frontocortical
noise itself as well as through the promotion of the release of other excitatory
ligands.
One potential explanation for the excessive cortical activation observed
following NMDAR hypoactivation involves the impairment of fast-spiking cortical
interneurons (Wilson et al., 1994; Markram et al., 2004; Homayoun &
Moghaddam, 2007). In the neurotypical brain, the interaction of glutamatergic
and GABAergic systems acts as an effective “acceleration” and “brake” system,

iv
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respectively, by which excitatory neurotransmission is regulated, helping to
maintain homeostatic signal transduction in cortical regions through a continuous
feedback loop (Carlsson et al., 2001). The overstimulation of NMDARs elicits the
GABAergic response, dampening excitatory neurotransmitter input to the cortex;
similarly, the underactivation of the glutamatergic system decreases the inhibitory
effects of the GABA interneurons. The suppressant function of GABA receptors
(GABARs) on the activity of glutamate and other excitatory neuropeptides is
dependent on adequate NMDAR input. Studies using microdialysis to examine
GABAergic outflow after the pharmacological blockade of NMDARs have
demonstrated that a hypofunctioning NMDAR system induces dysfunction in the
regulatory actions and spontaneous firing rate of these putative GABA
interneurons. GABAergic suppression disrupts the ability of these neurons to
lessen excitatory outflow to the cortex, leading to excessive stimulation of
prefrontal pyramidal neurons (Homayoun & Moghaddam, 2007). The failure of
these inhibitory mechanisms impairs a variety of cognitive processes through the
malfunction of excitatory neuromodulator activity and excessive frontocortical
activation.
Findings from studies using an assortment of cognitive and behavioral
assays have illustrated a relationship between NMDAR inhibition and deficits in
vigilance, learning, and memory. For example, Sakimura et al. (1995) showed
that mice with NR2A subunit gene disruption demonstrated substantially reduced
hippocampal LTP, negatively impacting spatial memory performance when
compared to wild-type mice. In a similar fashion, Bannerman and colleagues
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(2013), while failing to discern disparities in spatial memory performance
following deletion of CA1 NMDARs in the dentate gyrus and dorsal hippocampus,
observed deficits in the utilization of spatial information to make navigationrelated decisions in a water maze. In contrast to the previous experiment, Tsien,
Huerta, and Tonegawa (1996), using CA1 NMDAR knockout mice, confirmed
that the lack of this gene leads to a disruption in learning in the Morris water
maze as well as impaired spatial memory as measured by increased escape
latencies in the task.
The pharmacological inhibition of NMDARs yields similar behavioral
outcomes when compared to the genetic deletion of these receptors. Ketamine, a
dissociative anesthetic, is a non-competitive NMDAR antagonist known to reduce
calcium influx by binding inside of the ion channel, suppressing its overall firing
rate (Malhotra et al., 1996). Phencyclidine (PCP), similarly classified as a noncompetitive NMDAR channel blocker, also produced dysfunctions in
frontocortical excitatory neurotransmission and disturbed cognitive performance
during tasks dependent on balanced catecholamine concentrations in the PFC
(Zukin & Zukin, 1979; Morris, Cochran & Pratt, 2005). NMDAR antagonism
particularly exacerbates prefrontal DAergic activity, as the excessive stimulation
of non-NMDA glutamate receptors induces endogenous DA release
(Moghaddam et al., 1997). The glutamatergic-mediated augmentation of DA and
other monoamine concentrations in brain areas implicated in attention, learning,
and both working and long-term memory suggests that excitatory transmission
promotes cognition to a certain extent, but excessive excitatory activity becomes
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counterproductive in this regard, and NMDAR blockade incites hyperexcitationrelated deficits.
It has been speculated that impairment in NMDAR and non-NMDA
glutamate receptor function in the SZ brain contributes to profound cognitive
deficits. As has been confirmed by evidence from transcranial magnetic
stimulation (Rogasch, Daskalakis & Fitzgerald, 2014) and ligand binding (Deakin
et al., 1989) studies, there is overstimulation of glutamatergic afferents and an
increase in glutamatergic binding in cortical regions of the schizophrenic brain,
largely due to systematic failure of GABA interneuron-mediated cortical inhibition.
Rogasch, Daskalakis and Fitzgerald (2014) also revealed diminished long-range
corticolimbic connectivity in these individuals associated with aberration in small
populations of neurons that interact with these connections. General prefrontal
function is markedly reduced in SZ as well, and Beneyto et al. (2007) suggest
this may be largely due to reduced function of NMDAR afferents and their
contribution to numerous cognitive processes. Following this logic, drugs that are
able to ameliorate frontocortical hyperexcitation induced by dampened cortical
NMDAR inputs may be able to lessen SZ symptomology, particularly when
considering the negative cognitive, affective, and social tendencies.
The cholinergic system and schizophrenia
Cholinergic neurons, which release the neurotransmitter acetylcholine (ACh)
throughout the nervous system, are required for a wide variety of psychological
and behavioral phenomena. Being comprised of both ionotropic nicotinic ACh
receptors (nAChRs) and metabotropic muscarinic ACh receptors (mAChRs),
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activation of the basal forebrain cholinergic system (BFCS) in the typicallyfunctioning brain enhances cognition (Drachman, 1977). ACh efflux is particularly
elevated during attentionally-demanding tasks, with cortical cholinergic
projections playing a major role in mediating sustained attentional processing
and allocating vigilance-related resources (Sarter, Gehring & Kozak, 2006;
Dumas & Newhouse, 2011). The cholinergic network is especially involved in the
top-down, knowledge-based processing of relevant environmental stimuli as well
as the deemphasis of irrelevant information, and this process interacts with the
bottom-up input of sensory information to improve attentional performance
(Sarter et al., 2001). The degree to which a particular task is attentionallydemanding dictates the extent of basal forebrain cholinergic activation. The
ability of this system to filter out extraneous and distracting information while
simultaneously enhancing the detection of relevant stimuli makes the integrity of
corticopetal cholinergic projections required for attention and the processes that
depend on it, such as learning and working memory.
In the same vein, compromised cholinergic neurotransmission has been
linked to impairments in basic cognitive functioning, and dampened function of
cortical cholinergic innervation is a chief contributor to both age-related cognitive
impairments and those seen in individuals with neurodegenerative conditions
such as Alzheimer’s and Parkinson’s diseases (Coyle, Price & DeLong, 1983;
Perry et al., 1985; Everitt & Robbins, 1997). Similarly, suppression of basal
forebrain corticopetal neurons with cholinergic antagonists or the immunotoxin
192 IgG-saporin, for example, produces marked deficits in a number of measures
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relating to cognition, including visual attention and memory formation
(McGaughy, Kaiser & Sarter, 1995; Chudasama et al., 2004; Burk, Lowder &
Altemose, 2008; Hasselmo & Sarter, 2011).
Overactivation of these receptors impairs cognition as well, adhering to the
“inverted-U” phenomenon of neuronal stimulation. When considering the doseresponse association between BFCS activation and behavior, this parabolic
relationship suggests that both sub-threshold and elevated ACh levels have a
counterproductive impact on a variety of physiological and psychological
processes while moderate levels of activation demonstrate beneficial qualities
(Picciotto, 2003). In the typically-functioning brain, reduced concentrations of a
cholinergic ligand do not tend to elicit effects on behavior, but too high of a
concentration can overstimulate these receptors and induce a hypercholinergic
state. Excessive output from basal forebrain neurons has been shown to diminish
the cortical signal-to-noise ratio and bolster sensory stimuli-evoked discharge,
inciting disturbances in both cognitive and sensory processes (Donoghue
&Carroll, 1987; Perry & Perry, 1995). The capacity for potent cholinergic agents
to dampen both bottom-up and top-down processing of cognitive and sensory
information further validates the necessity of the BFCS in modulating intellectual
and perceptual systems.
Because of the crucial role this system plays in cognitive functioning,
dysregulation of basal forebrain projections to the cortex is suggested to
contribute to the pathology of SZ. Previous research examining cholinergic
receptors in the etiology of SZ support the notion that cholinergic output from the
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basal forebrain is elevated in the SZ brain, likely contributing to both the positive
and negative symptoms of the disorder (Tandon & Greden, 1989). Glutamate
receptors are located on basal forebrain corticopetal cholinergic neurons. Thus,
these cortically projecting cholinergic neurons show an elevated firing rate in the
presence of augmented glutamate release resulting from NMDAR regulatory
failure (Fadel, Sarter & Bruno, 2001). In a state of cortical hyperexcitation
induced by NMDAR and GABAR hypofunction, amplified ACh release has been
shown to reduce performance in a wide variety of cognitive measures. As
discussed by Tandon and Greden (1989), for individuals with SZ, excessive
frontocortical cholinergic activity – believed to stem predominantly from mAChR
overactivation – diminish attentional performance by increasing the perception
and processing of irrelevant stimuli. In congruence with this idea, the atypical
antipsychotic medication clozapine is believed to elicit some of its therapeutic
effects through mAChR antagonism (Bolden, Cusack & Richelson, 1991; Meltzer
& McGurk, 1999). Finally, both the density of and the binding at nAChRs and
mAChRs are significantly decreased throughout cortical and striatal structures of
the schizophrenic brain (Durany et al., 2000; Crook et al., 2001; Marutle et al.,
2001; Terry, 2008; Scarr et al., 2009). This reduction in receptor reactivity is likely
a product of their desensitization, as is known to occur following chronic
cholinergic overstimulation (Nastuk & Wolfson, 1976).
One very common and accessible way by which individuals with SZ are
speculated to self-medicate is by smoking cigarettes. While 25 to 30 percent of
the general population smokes on a regular basis, anywhere from 80 to 90% of
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those afflicted with SZ are habitual cigarette smokers (Ripoll, Bronnec & Bourin,
2004). Nicotine, the primary psychoactive ingredient in cigarettes, is known to
demonstrate cognition-enhancing characteristics for those with and without a
diagnosis of SZ; interestingly, however, the mechanisms underlying nicotine’s
beneficial qualities for people with SZ differ from those with a neurotypical brain.
In particular, nicotine is considerably more reinforcing for those with SZ due to its
capacity to temporarily relieve sensory and cognitive disturbances exacerbated
by superfluous cholinergic activity. Nicotine administration has been shown to
normalize deficits in inhibitory sensorimotor gating, including P50 auditory gating
and prepulse inhibition (Siegel et al., 1984; Adler et al., 1993). When considering
measures of cognition, following a period of forced abstinence in a study
conducted by Sacco and colleagues (2005), habitual smokers with SZ performed
more poorly on sustained attention and spatial working memory tasks than nonschizophrenic smoking controls. These impairments in performance were
alleviated following reinstatement of cigarette-smoking; if those with SZ were pretreated with mecamylamine hydrochloride, a non-selective nAChR antagonist,
nicotine failed to alleviate these cognitive deficits.
There are a number of ways through which nicotine administration is able
to normalize dysregulated excitatory neurotransmission in the brains of persons
with SZ. One method involves targeting low-affinity alpha-7 (α7) nAChRs, which
have been shown to augment NMDAR firing. Nicotine exerts its effects
presynaptically, thereby releasing glutamate onto postsynaptic NMDARs. A
synergistic effect has been observed when α7 nAChRs and NMDARs are
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simultaneously stimulated (Aramakis & Metherate, 1998). Many hippocampal α7
nAChRs both terminate onto and share synapses with voltage-gated NMDARs,
suggesting that activity at this nAChR subtype modulates glutamate-induced
excitatory post-synaptic potentials to a degree (Zappetini et al., 2014). Armakis
and Metherate go on to suggest that, in effect, α7 nAChR stimulation may be
required for these particular NMDARs to activate. Zappettini et al. (2014), by
utilizing a non-metabolizable tracer, calcium imaging, and immunocytochemical
assays to quantify the impact of nicotine pre-exposure on NMDAR activation,
revealed that the increase in NMDAR-mediated glutamatergic outflow is present
in the nucleus accumbens (NAcc) and, to a slightly lesser extent, hippocampal
nerve terminals. This effect was not present following stimulation of alpha-4 beta2 (α4β2) nAChRs, as this receptor subtype was found to reduce presynaptic
GluN2B-containing NMDAR activation when agonized. In the context of the
NMDAR hypofunction model of SZ, pharmacotherapies that stimulate normally
underactive NMDARs, such as α7 nAChR agonists, may help to normalize
frontocortical excitatory neurotransmission.
The crucial interaction between NMDARs and nAChRs is further validated
by studies examining the behavioral effects of nicotine and similar compounds
following NMDAR blockade. For instance, nicotine administration ameliorates
deficits in prepulse inhibition induced by PCP, denoting its therapeutic potential
for alleviating sensorimotor dysregulation (Spielewoy & Markou, 2004). Mice
given the α7 nAChR agonist SSR180711 for two weeks following a ten-day
period of sub-chronic PCP administration demonstrated significantly improved
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performance in a novel object recognition test compared to those given saline
after PCP exposure (Hashimoto et al., 2008). Mice that were systematically
administered the potent NMDA receptor antagonist MK-801 prior to placement in
a fear conditioning task were able overcome NMDAR blockade-induced learning
deficits when also receiving bilateral nicotine infusions (André, Leach & Gould,
2011). Yang et al. (2013) antagonized α7 nAChRs in the dorsolateral PFC and
discovered that, largely through the suppression of NMDAR activity, there was a
marked reduction in the attentional modulation of the visual cortex and, therefore,
representation of space in the primate. Low doses of nicotine, however,
enhanced these visual representations. Thus, due to the interactions between
these two networks, α7 nAChR stimulation is able to remediate cognitive deficits
resulting from suppression of NMDAR activation.
Another potentially beneficial aspect of nicotine that helps to alleviate
frontocortical hyperexcitation involves reducing elevated ACh levels via
GABAergic stimulation. Cholinergic neurons from the basal forebrain innervate
the hippocampus through the septo-hippocampal pathway, which is a bidirectional network that modulates ACh release primarily through the activation of
GABAR projections to the BFCS (Dutar et al., 1995; Khakpai et al., 2013).
Stimulation of α7 nAChRs has shown to inhibit basal forebrain cholinergic activity
through the promotion of GABAergic input from these hippocampal innervations
(Alkondon et al., 2000; Maggi, Sher & Cherubini, 2001). Through the mild
suppression of corticopetal cholinergic activity, cortical overstimulation in SZ can
be quelled and some aspects of cognition can be temporarily restored. Agonists
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that target the α7 nAChR subtype demonstrate similar cognition-boosting
properties as well, and such drugs have been suggested to offer promise as both
monotherapy and adjunct therapy for SZ (Martin, Kem & Freedman, 2004).
Nicotine is also well-known to boost DA release in the NAcc, ventral tegmental
area (VTA), and PFC, helping to address the problem of hypofrontality in SZ
patients (Corrigall & Coen, 1991; Corrigall, Coen & Adamson, 1994; Dalack,
Healy & Meador-Woodruff, 1998).
One issue with nicotine, however, is that it more effectively stimulates
α4β2 nAChRs compared to α7 nAChRs. Because activity at α4β2 nAChRs
promotes cholinergic neurotransmission, symptoms related to psychosis can be
worsened by cigarette smoking and nicotine self-administration. Not only is the
α4β2R subtype more commonly expressed than its α7 counterpart, but both
nicotine and the endogenous ligand bind more efficiently to these receptors (De
Luca et al., 2006). The α4 subunit of the α4β2 nAChR is especially implicated in
striatal basal DA release, largely contributing to nicotine’s rewarding qualities for
smokers both with and without SZ. While activity at α7 nAChRs may alleviate
some of the symptoms of SZ – namely those related to cognition – it may also
increase the likelihood of a psychotic episode, mediated primarily through the
exacerbation of already-elevated mesolimbic DA concentrations. This idea is also
supported by the capacity for nicotine to diminish the antagonist effects of
antipsychotics at D2Rs by augmenting cortical DA release, occasionally
necessitating an increase in dosage of these drugs (Pierre, 2005).
Measurements of DA efflux resulting from nAChR activation following systematic
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intracranial infusions of nicotine revealed that, over time, less cortical DA was
being released following nicotine due to the desensitization of both nAChRs and
DARs (Marks, Grady & Collins, 1993). Thus, while demonstrating some transient
cognition-enhancing properties, nicotine as a method of self-medication is
unsuitable as a long-term treatment option.
The orexinergic system and SZ
The orexinergic network is believed to play a crucial role in cognition. Also
called hypocretins, orexins are considered the primary wakefulness
neuromodulators in the brain, acting as a regulator of both circadian and
appetitive processes (Sakurai et al., 1998; Saper, Scammell & Lu, 2005). This
neuronal network, which is comprised of approximately 70,000 neurons in
humans and originates in the lateral hypothalamus and adjacent perifornical area
(PFA), was first discovered in 1996 by Gautvik, de Lecea and colleagues and
later classified by both de Lecea and Sakurai in separate studies in 1998. The
orexinergic system consists of orexin-A (OxA) and orexin-B (OxB) endogenous
isoforms (collectively referred to as orexins), derived from the same amino acid
precursor prepro-orexin, as well as G-protein coupled orexin-1 (Ox1R) and
orexin-2 (Ox2R) receptors. While OxB has low affinity to Ox1Rs and elicits most
of its effects through Ox2R stimulation, OxA displays equally potent activation of
both Ox1Rs and Ox2Rs (Hagan et al., 1999). OxA and OxB induce a biphasic
calcium response when binding at orexinergic receptors, both releasing
intracellular calcium via phospholipase C as well as promoting an influx of
calcium from the extracellular space (Smart et al., 1999). Unlike other
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hypothalamic neuropeptides, OxA and OxB have been shown to facilitate the
release of both GABA and glutamate when acting at axon terminals, which,
together, regulate virtually all hippocampal excitatory neurotransmission (van den
Pol et al. 1998; Chemelli et al., 1999).
As has been established in both in vitro and in vivo recording studies, Cfos expression in orexin neurons is highest during the day hours in diurnal
animals, increasing feelings of wakefulness and promoting hunger, whereas
without exposure to daylight cues, the activity of the orexinergic network is
suppressed and both arousal and food-seeking behaviors are reduced (Willie et
al., 2001). In fact, these cells must be effectively “switched off” to maintain both
consolidated NREM stages and the muscular atonia associated with REM sleep
(Sakurai, 2007). Activity of these cells is transiently augmented following sensory
stimulation and emotional perturbance, suggesting that the system is markedly
sensitive to sensorimotor processes and psychological drives (Mileykovskiy,
Kiyashchenko & Siegel, 2005). For those with narcolepsy, hypofunctioning
Ox1Rs and especially Ox2Rs generate abnormal patterns of arousal, inducing
daytime somnolence in addition to frequent bouts of cataplexy and
unconsciousness (Lin et al., 1999). Those that suffer from narcolepsy and related
sleep disorders also tend to demonstrate deficits in cognitive performance (Fulda
& Schulz, 2001). The necessity of the orexinergic activation in regulating
circadian rhythmicity and maintaining an enduring state of wakefulness suggests
that OxA and OxB are two significant neurological correlates of consciousness;
thus, it can be postulated that this system likely contributes in some capacity to
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the cognitive processes that are enhanced in a state of increased arousal and
alertness.
In support of this proposition, stimulation of Ox1Rs and Ox2Rs have been
found to improve attention, learning, and working memory, primarily by instigating
the release of wakefulness-promoting and cognition-enhancing neuropeptides.
The orexinergic system projects all throughout the brain and interacts with not
only structures related to consciousness, but many midbrain and forebrain
structures implicated in cognitive processes, such as the locus coeruleus,
amygdala, paraventricular nucleus of the thalamus, VTA, and infralimbic and
prelimbic prefrontal cortical areas (Peyron et al., 1998; Ebrahim et al., 2002;
Fadel & Deutch, 2002). In neurotypical, well-rested organisms, targeting OxRs
has negligible effects on attentional and cognitive performance, likely due to the
normal activation of this network. However, in sleep-deprived individuals,
administration of OxA alleviates cognitive impairment induced by lack of sleep
(Deadwyler et al., 2007). Similarly, the inhibition of Ox1Rs has been
demonstrated to impair cognition. Rats given both systematic and intrabasalis
SB-334867, an Ox1R antagonist, and placed in a sustained attention task
revealed substantial reductions in the ability to correctly identify the occurrence of
a brief visual stimulus (Boschen, Fadel & Burk, 2009; Fadel & Burk, 2010). The
suppression of sustained attentional capacity elicited by Ox1R antagonism is
similar to that observed follow loss of basal forebrain corticopetal cholinergic
neurons. The inactivation of these neurons with SB-334867, too, precludes
acquisition, consolidation and retrieval of spatial memories related to
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performance in the Morris water maze, highlighting the importance of the
orexinergic system at multiple stages of cognition (Akbari, Naghdi & Motamedi,
2006).
Hypothalamic orexinergic neurons are thought to play an important
modulatory role in cognition enhancement, in part, because they augment
excitatory neurotransmitter levels, including norepinephrine (NE), histamine, and
especially DA in the mesocorticolimbic DA circuit (Peyron et al., 1998). The
BFCS is innervated by lateral hypothalamic orexinergic fibers (Nambu et al.,
1999). Findings from ultrastructural and light microscopy studies have found that
around 70% of medial septal cholinergic neurons contain orexin immunoreactive
appositions on their dendrites or cell bodies (Wu et al., 2004; Fadel, Pasumarthi
& Reznikov, 2005; Fadel & Frederick-Duus, 2008). While both Ox1Rs and Ox2Rs
are found throughout the basal forebrain, Eggermann and colleagues (2001)
speculate that, because OxB administration more effectively depolarizes
cholinergic neurons when compared to OxA, Ox2Rs are more highly expressed
in this region and are primarily responsible for the cholinergic effects of
orexinergic activation. Fadel and Burk (2010) propose that projections of orexin
neurons to the basal forebrain create an anatomical substrate for the relationship
between arousal and attention, augmenting the release of ACh to the cortex and
promoting a state of alertness and vigilance. The activation of the cortex via
orexin-mediated cholinergic release is believed to underlie the cognitionpromoting characteristics of compounds that boost activity at this system.

OXA ON MK-801-INDUCED ATTENTIONAL DEFICITS

21

OxA has also demonstrated nAChR-stimulating properties. By using twophoton imaging and examining slices from rat PFCs, Lambe et al. (2005) were
able to reveal a sizeable amount of shared thalamocortical synaptic activity in the
PFC following both OxB and nicotine administration. Due to the measurably
similar actions of these two receptor systems, it may be the case that orexins
would have similar stimulatory and cognition-enhancing effects as nicotine. To
test this possibility, Lambe and colleagues bilaterally infused nicotine and OxB
into the medial PFC of rats engaged in an attention task which assessed
detection of a 0.3 s or 1 s visual stimulus. Task accuracy was significantly
increased by both nicotine and the larger of two OxA doses, compared to saline,
during trials with the shorter signal duration. As such, by examining both neural
activity and attentional processing, it has been confirmed that, to a large extent,
OxA is able to activate the thalamocortical arousal pathway in a similar manner
as nAChR stimulation. Additionally, nicotine consumption increases Fos
expression in orexin-containing neurons of the hypothalamus, potentially
underlying some of the therapeutic benefits of cigarette smoking in SZ
(Pasumarthi, Reznikov & Fadel, 2006).
Despite the propensity for this network to promote cognition when
activated, limited research has been conducted regarding the contribution of
these neurons in SZ symptomology, particularly the negative symptoms. Chien et
al. (2015) measured plasma concentrations of OxA of individuals with and
without a diagnosis of SZ and discovered that OxA levels were substantially
higher in a small subset of SZ-afflicted persons. Compared to SZ patients with
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typical OxA levels, those in the group with elevated OxA plasma concentrations –
comprising around 20 percent of the sample – displayed less cognitive and
disorganized symptoms as determined by a substantial reduction in preservation
errors on the Wisconsin Card Sorting Test (WCST), suggesting that increased
orexinergic activity may be able to attenuate the negative syndrome. While the
behavioral effects of orexins or orexin-like analogs have not been examined in
models of SZ, it has been shown that modafinil, a wakefulness-promoting agent
that augments the release of hypothalamic histamine through orexinergic
stimulation, alleviates cognitive and attentional deficits in individuals with SZ
(Ishizuka et al., 2003; Turner et al., 2004; Hunter et al., 2006). However, as
modafinil acts in a variety of ways, including blocking the reuptake of DA, its
cognition-enhancing properties cannot be attributed solely to the activation of this
system, necessitating the exploration of pharmacotherapies acting primarily at
Ox1Rs and Ox2Rs in the context of SZ.
Research hypotheses
Since the discovery of orexins in the 1990’s, a wealth of useful information
has been uncovered regarding the capacity of orexins to induce wakefulness and
increase appetite. More recently, the role of OxA in cognition was detailed, and
due to its cognition-enhancing qualities, it has been suggested to potentially
alleviate the cognitive deficits associated with SZ. Because the negative
syndrome is notoriously treatment-resistant and correlates strongly with poor life
outcomes, there is an impetus to explore the potential of this cognition-enhancing
neuropeptide in alleviating these pervasive symptoms. As was previously
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detailed, the NMDAR hypofunction hypothesis of SZ suggests that cognitive and
perceptual abnormalities emerge from a marked reduction in hippocampal
NMDAR input, inducing GABAergic dysfunction and significantly augmenting
frontocortical excitatory neurotransmission. A commonly-utilized method to
reproduce this effect in rodents is with the administration of NMDAR antagonists,
as these drugs have demonstrated the ability to emulate many of the
neurological and behavioral abnormalities that are present in those with SZ
(Mohn et al., 1999; Coyle, 2012).
While dopaminergic agonists such as amphetamines are effective in
emulating the positive syndrome of SZ, NMDAR antagonists have demonstrated
the capacity to encompass both positive and negative aspects of this disorder
(Luby et al., 1959; Snyder, 1980). By binding to a hydrophobic site within the ion
channel, these drugs effectively preclude the depolarization of NMDARs.
Compounds frequently utilized in pharmacological models of SZ include
ketamine, PCP, and MK-801 (Kapur & Seeman, 2002). MK-801, also referred to
as dizocilpine, is the most potent NMDAR antagonist of the three and has
demonstrated the capacity to elicit widespread social, cognitive, and perceptual
dysregulation associated with SZ. At sufficient doses, typically at or exceeding
0.1 mg/kg, MK-801 administration produces social withdrawal (Rung et al.,
2005), attentional deficits (Howe & Burk, 2007), learning and memory impairment
(Butelman, 1989; de Lima et al., 2005), and motor aberrations including
hyperactivity (Hargreaves & Cain, 1992) in rodents. Due to the robustness of this
powerful NMDAR antagonist in accurately emulating the psychological and
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behavioral irregularities frequently observed in patients with SZ, MK-801 was
selected to reproduce the NMDAR hypofunction established in SZ for the present
study.
One goal of this project is to increase the translational potential of any
treatments. Intranasal administration offers a relatively easy, painless method of
drug delivery. Because OxA – but not OxB – is easily able to diffuse through the
blood brain barrier, and because OxA has been shown to enhance attentional
performance, OxA was administered intranasally in the current experiment
(Kastin & Akerstrom, 1999; Dhuria, Hanson & Frey, 2009; Zajo et al., 2016).
When compared to oral and intravenous routes of administration, mist or liquid
introduced through the nose also allows for more rapid onset of a drug’s effects
due to rapid uptake through the nasal membrane (Thorne et al., 2004). In support
of this, the efficacy of OxA facilitated intranasally surpassed that of OxA
injections in reversing the effects of sleep deprivation on cognitive performance
(Deadwyler et al., 2007). By utilizing OxA in this fashion, not only is its role as a
potential cognition-enhancer in SZ able to be elucidated, but the clinical efficacy
of intranasal OxA administration can be further explored.
Because OxA has previously demonstrated the capacity to alleviate
cognitive impairment in certain conditions, such as in sleep-deprived organisms,
it might be hypothesized to ameliorate the negative syndrome of SZ more
effectively than modern antipsychotic medications. Alternatively, levels of ACh, a
neurotransmitter critical for attention, are elevated in the MK-801 SZ model;
because of this, it may be that further stimulation of the ACh system with OxA
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may be detrimental to performance on a number of cognitive measures. To
further elucidate OxA’s role as a cognitive-enhancing pharmacotherapy in the
context of SZ, following training on a previously-validated sustained attention
task, the effects of various doses of intranasal OxA were examined in tandem
with MK-801 injections (McGaughy & Sarter, 1995). In this attentional paradigm,
subjects were required to correctly differentiate between signal and non-signal
trials (wherein a brief flash of a visual stimulus either does or does not occur)
during varying periods of time in order to attain reinforcement. We anticipated
that, in the absence of OxA, attentional performance would be significantly
impaired for rats given MK-801. By intranasally administering OxA following MK801 injections, OxA’s capacity to ameliorate the treatment-resistant cognitive
deficits stemming from NMDAR hypofunction was explored in a rodent model of
SZ.

OXA ON MK-801-INDUCED ATTENTIONAL DEFICITS

26

Chapter 2. Methods and Results
Methods
Subjects
12 male Fischer 344 Brown Norway F1 hybrid rats, bred at Charles River
Laboratories (Wilmington, MA) and weighing between 250 and 350 g at the
beginning of behavioral training, were utilized throughout the duration of the
experiment. All behavioral testing occurred at least six days per week between
the hours of 9AM and 4PM. Rats were housed in pairs throughout the entirety of
the protocol and were allotted ad libitum access to rodent chow, but they were
placed on a water restriction schedule to establish tap water as a reinforcer for
accurate performance in the task. On testing days, rats were given access to a
water bottle for ten minutes following their time in the task and they received 20
minutes of water access on days when they were not tested.
Apparatus
Each rat was trained in one of 12 operant boxes from Med Associates
Inc., with all task procedures and data collection controlled by MedPC IV
software (Georgia, VT). Each box consisted of an intelligence panel with left and
right retractable levers, access to a water dipper with a 0.01 ml cup, and a
stimulus light centralized above the water port. A house light was situated on the
opposite wall facing the intelligence panel and remained illuminated throughout
the testing session. Each box was located inside of a sound-attenuating
chamber.
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Procedure
Animal training
Rats trained in three phases to reach criterion performance in the
sustained attention task. In the initial stage, rats were shaped to press the right
and left levers approximately equally to maximize reinforcement. In order to
protect against the development of side bias, responses were reinforced on a
fixed ratio (FR1) schedule, with the stipulation that if the rat pressed one lever
five consecutive times, it needed to press the other lever to receive reward
access. A lever press that met this criterion led to the 0.01 ml water dipper being
raised for three seconds. Once they attained 120 total rewards over a span of
three days, the rats were moved to the attention task with correction trials.
In this second phase of training, rats were shaped to discriminate between
signals (illumination of the central panel light for one second) and non-signals
(the central panel light did not illuminate). The inter-trial interval (ITI) was 12±3 s,
randomized to prevent possible anticipation of the commencement of a new trial.
After the ITI, a signal was presented or there was no illumination of the central
panel light and then both levers were extended for three seconds. The rules of
the task were counterbalanced such that half of the rats were trained to press the
right lever to indicate detection of the 1 s signal and press the left lever in the
absence of this light; conversely, for the other half of the rats, a left lever press
was rewarded in signal trials and a right lever press was reinforced in non-signal
trials. If the rats responded incorrectly – that is, pressing the signal lever when no
signal is presented (false alarm), pressing the non-signal lever when a signal is
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presented (miss), or by failing to press altogether within 3 sec of when the levers
were inserted into the chamber (omission) – a correction trial ensued. The
correction trial was identical to the previous trial. If the rat made three
consecutive incorrect lever presses during correction trials, a forced trial occurred
wherein only the correct lever was extended into the chamber. The central panel
light remained illuminated during forced trials that resulted from errors on signal
trials. These trials only ended once the correct lever was pressed or 90 seconds
had passed. After the rat correctly identified the presence (hit) and absence
(correct rejection) of the signal light at a rate of 70% or higher for three
consecutive days, they progressed to the final version of the task.
In the last phase of training, rats were trained to detect signals of varying
durations – 500, 100, and 25ms – without the inclusion of correction trials. While
the 500 ms is not difficult to detect for rats, correctly identifying the shorter signal
durations, especially the 25 ms signal, increases the attentional demands of the
task. Also, variable signal durations increase attentional demands relative to
sessions with a single signal (Koelga, 1987). Each testing session lasted
between 35 and 40 minutes and contained 162 trials that were evenly split
between signal and non-signal trials, with an equal number of trials at each signal
duration. In order to further augment the degree to which the task taxes
attentional resources, the ITI was reduced to 9±3 s (McGaughy & Sarter, 1995),
in order to increase the rate at which rats attended to the presence or absence of
the visual signal. When rats answered incorrectly in this task, they were not
allowed access to water at the conclusion of the trial. The behavioral criteria were

OXA ON MK-801-INDUCED ATTENTIONAL DEFICITS

29

70% or higher accuracy in identifying both 500 ms signal trials and non-signal
trials for three successive days. Once rats achieved these criteria, they were
considered eligible for inclusion in the present experiment.
MK-801 and OxA preparation
MK-801 was purchased from Tocris Bioscience (Bristol, United Kingdom).
A stock solution of 0.125 mg/kg MK-801 maleate in sterile saline was prepared
and then pipetted into aliquots and stored in a freezer. The prepared solution was
utilized within one week of its initial freezing. On a testing day, an aliquot was
diluted, as needed and only used on that one testing day.
OxA was also purchased from Tocris Bioscience. Stock OxA
concentrations of 5nM and 10 nM were prepared and then frozen and stored for
the duration of the experiment. All aliquots were thawed immediately before use.
Drug administration
After rats reached criterion task performance, they began a week-long
period to acclimate to intranasal administration wherein 25 µL saline was
administered per nare daily. To accomplish this, the saline was pipetted and, with
the rat’s nostrils oriented upwards, administered in small droplets that were then
inhaled through the nose. Once the animals had received seven days of
intranasal saline, drug administration commenced.
Drug administration sessions were conducted in a completely withinsubject design, with every subject receiving a total of nine distinct combinations
of MK-801 (0 mg/kg, 0.075 mg/kg, and 0.125 mg/kg) and OxA (0 nM, 5 nM, and
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10 nM). During a day of testing, a randomized MK-801-OxA dose pairing was
selected for each rat to protect against order effects, and at least one day
separated drug administration sessions to minimize potential interactions from
prior drug administration. Because the full range of effects induced by MK-801
are present in less than half an hour after its administration, rats were given
intraperitoneal injections of one of the three concentrations of MK-801 20
minutes before testing (Pinault, 2008). After 15 minutes had passed following
MK-801 injections, 50 µL of either 0 nM, 5 nM, or 10 nM of OxA was
administered intranasally at a volume of 25 µL per nare. Following a one minute
acclimation period, rats were then placed in the attention task. This procedure
was repeated on each day of drug administration until all possible combined
doses of MK-801 and OxA had been given prior to task performance.
Data analyses
Data analysis entailed calculating the total number of hits and misses at
the 500, 100, and 25 ms levels as well as correct rejections, false alarms, and
omissions per testing session. Signal detection accuracy in the task was
determined by dividing total number of hits at each signal duration by the sum of
the hits and misses at that specific signal length (h/(h+m)). These calculations,
considered relative hits, were generated for each MK-801-OxA dose combination
and signal duration combination per animal. Likewise, the proportion of relative
correct rejections for non-signal events was determined by dividing total number
of correct rejections by number of correct rejections and number of false alarms
(cr/(cr+fa)) for each combination of drug treatment. Repeated-measures
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ANOVAs and paired-sample t-tests, which were corrected with the Bonferroni
procedure, were conducted using SPSS (version 23.0, Chicago, IL).
Results
In a 3 (MK-801; 0, 0.075, and 0.125 mg/kg) × 3 (OxA; 0, 5, and 10 nM) × 3
(signal duration; 500, 100, and 25 ms) repeated measures ANOVA for relative
hits, MK-801 elicited a main effect on performance in the sustained attention
task, F(2,22) = 8.231, p = .002 (Figure 1). Paired samples t-tests averaging
across OxA concentration revealed that, while relative hits at the two lower MK801 doses did not differ, signal detection accuracy at 0.125 mg/kg (M = 0.444,
SD = 0.321) was significantly lower than both 0 mg/kg (M = 0.706, SD = 0.109;
t(11) = 2.985, p = .012) and 0.075 mg/kg (M = 0.673, SD = 0.259; t(11) = 2.440, p
= .033). In addition to this main effect, an interaction between OxA dose and
signal duration was discovered, F(4,44) = 2.712, p = .042 (Figure 2). To further
elucidate this, one-way ANOVAs averaging across MK-801 dose and examining
OxA dose as a factor at each signal duration were conducted, but none of these
analyses yielded significant results.
Due to the high omission rates at 0.125 mg/kg of MK-801, examining the
highest dose with this measure of accuracy may not be appropriate due to
skewed hit percentages. To address this issue, an additional 2 (MK-801) × 3
(OxA) × 3 (signal duration) repeated measures ANOVA excluding the largest
concentration of MK-801 was conducted. The main effect of MK-801 yielded by
the previous analysis was no longer significant after the removal of the highest
dose, as 0.075 mg/kg did not impair attentional performance. Despite this failure
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of MK-801 to induce deficits in signal detection, an MK-801 × OxA × signal
duration interaction was revealed, F(4,44) = 2.630, p = .047. To assess the basis
for this interaction, 2 (MK-801) × 3 (signal duration) repeated measures ANOVAs
were conducted at each of the three OxA concentrations to further elucidate this
relationship. An MK-801 × signal duration interaction was found after intranasal
administration of saline, F(2,22) = 6.805, p = .005 (Figure 3). Despite this, when
determining if performance at any of the three signal durations had significantly
changed from 0 to 0.075 mg/kg of MK-801, paired samples t-tests exploring this
relationship yielded no significant outcomes; only during 100 ms trials was signal
detection accuracy almost significantly decreased from 0 to 0.075 mg/kg
following intranasal saline exposure, t(11) = 1.971, p = .074. No MK-801 × OxA
interactions were uncovered at 5 nM or 10 nM of OxA.
A 3 (MK-801) × 3 (OxA) repeated measures ANOVA was utilized to
examine the effects of MK-801 and OxA on the rats’ accuracy on non-signal
trials. This analysis yielded a main effect of MK-801, F(2,22) = 6.099, p = .008
(Figure 4). Paired samples t-tests revealed that correct rejections were lower
following injections of 0.125 mg/kg MK-801 compared to vehicle, t(11) = 2.859, p
= .016, or to 0.075 mg/kg MK-801, t(11) = 2.382, p = .036. In addition to this main
effect, there was a significant interaction between MK-801 and OxA, F(4,44) =
3.063, p = .026. To further elucidate this finding, three repeated measures
ANOVAs with OxA dose as a factor were conducted for each of the MK-801
concentrations. These analyses revealed that there was a main effect of OxA in
the absence of MK-801 (vehicle administration), F(2,22) = 4.350, p = .026.
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Subsequent paired samples t-tests revealed that relative correct rejections for
either OxA dose were not significantly different compared with intranasal saline
administration. However, correct rejection accuracy following 5 nM OxA was
significantly lower than following 10 nM OxA, t(11) = 2.262, p = .045. One
potential concern is that the MK-801 × OxA interaction for correct rejections may
be influenced by completion of relatively few trials at the highest MK-801 dose.
However, a 2 (MK-801) × 3 (OxA) repeated measures ANOVA, excluding the
highest MK-801 concentration still yielded a significant MK-801 × OxA
interaction, F(2,22) = 5.296, p = .013.
For omissions, a 3 (MK-801) × 3 (OxA) repeated measures ANOVA
revealed a main effect of MK-801 concentration, F(2,22) = 5.296, p = .013
(Figure 5). Omissions after injections of saline were lower than following
injections of 0.075 mg/kg of MK-801, t(11) = 4.781, p = .001, omissions at 0.075
mg/kg were less than 0.125 mg/kg, t(11) = 3.138, p = .009, and, lastly, omissions
after saline injections were substantially less than following 0.125 mg/kg, t(11) =
5.772, p < .001. The main effect of OxA approached significance (F(2,22) =
3.116, p = .064), but there was no interaction between the two drugs. Pairedsamples t-tests examining the impact of each dose of OxA on omission rates
averaging across MK-801 concentration unveiled that trial omissions were almost
significantly higher after intranasal saline when compared to 5 nM of OxA (t(11) =
2.176, p = .052) and at 10 nM when compared to 5 nM, t(11) = 2.023, p = .068
(Figure 6).
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Chapter 3. Discussion and Conclusion
Discussion
The present experiment was designed to test two separate drugs’ effects
on sustained attentional processing. Firstly, it aimed to reproduce the robust
finding that MK-801 is a cognition-impairing agent and worsens performance in
this task. Secondly, this experiment tested whether intranasal OxA administration
could reduce attentional deficits following NMDAR blockade. In the context of
psychiatric illness, the current research employed a previously-utilized model of
SZ, and the potential for OxA – which has been found to demonstrate cognitiveenhancing qualities – to remediate the negative cognitive symptoms. Overall, it
was found that the large dose of MK-801 had negative implications for attentional
performance across all measures of accuracy in the task and that OxA
administration had no effect or tended to worsen these impairments. Therefore,
based on the results of this experiment, it is likely that OxA would not be an
appropriate pharmacotherapy in this SZ model.
OxA on measures of attentional performance following MK-801 administration
The highest MK-801 dose had a profoundly negative impact on hit
accuracy. OxA itself did not significantly affect signal detection in the task
following MK-801 administration. Thus, the hypothesis that intranasal OxA could
reverse attentional impairments following MK-801 administration was not
supported. Similarly to relative hit performance, MK-801, at the highest
concentration, significantly reduced the ability of the rats to accurately respond
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on non-signal trials. Again, once the 0.125 mg/kg concentration was removed
from the analyses, the ability of MK-801 to induce these attentional deficits
disappeared. The most interesting findings were the effects following 0, 5, and 10
nM OxA in the absence of MK-801. After an injection of only saline, correct
rejections at 5 nM were reduced when compared to 10 nM OxA, but neither dose
was markedly different when compared to intranasal administration of vehicle.
The basis for this effect is unclear, but further experiments assessing the spread
of different intranasal OxA doses among brain regions may be useful in clarifying
why performance was worse following the lower OxA dose compared with the
higher OxA dose. There was no notable effect of OxA concentration following
exposure to MK-801. Finally, MK-801 also elevated omission rates.
A likely reason that OxA was unable to alleviate NMDAR blockadeassociated attentional deficits is due to its capacity to promote frontocortical ACh
release. Lateral hypothalamic orexinergic cells stimulate basal forebrain
cholinergic neurons, and augmenting activity at these receptors appears to
further exacerbate the already-overactive cholinergic system present in SZafflicted individuals. As was previously detailed, a surplus of cholinergic input in
the cortex leads to the overstimulation of various sensory and perceptual
systems by weakening the brain’s ability to filter irrelevant environmental stimuli,
and it is likely that elevated frontocortical ACh, in congruence with overstimulated
PFC pyramidal cells resulting from NMDAR hypofunction, worsens cognitive
performance (Donoghue & Carroll, 1987; Perry & Perry, 1995; Homayoun &
Moghaddam, 2007). As a consequence of excessive excitatory
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neurotransmission in both cortical and subcortical regions, it may be that the rats’
visual system was stimulated to such an extent that there was an impairment in
filtering whether or not a visual cue was presented. This notion is supported by
the finding that, while relative hits were not impaired by combinations of MK-801
and OxA, high concentrations of exogenous OxA, in congruence with NMDAR
blockade, appeared to somewhat worsen relative correct rejections, leading them
to err on the side of signal detection. Drugs that primarily act at α7-nAChRs,
which facilitate the activity of inhibitory septo-hippocampal GABAergic
innervations of the basal forebrain, demonstrate promise in alleviating SZ
symptoms; however, perhaps because OxA promotes ACh release at other
cholinergic receptor sites, it does not possess this therapeutic effect.
As MK-801 concentration increased, omission rates also increased in a
dose-dependent manner. Omissions were elevated at 0.075 mg/kg of MK-801
when compared to injections of saline, and omissions were higher at 0.125
mg/kg than at 0.075 mg/kg. A near-significant main effect of OxA revealed that
rats tended to omit slightly more often after intranasal saline and 10 nM of OxA
when compared to 5 nM, suggesting that perhaps small concentrations of OxA
help to protect against NMDA antagonism-induced elevations in trial omissions.
While no noteworthy motor aberrations were observed before or shortly after
engagement in the attention task, it is possible that increased concentrations of
MK-801 disrupted motor functioning and interfered with movements related to
lever-pressing (Tricklebank et al., 1989).
Implications of OxA treatment in SZ
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In a SZ model using NMDA receptor blockade, the introduction of
pharmacotherapies enhancing OxA activity do not improve measures of
sustained attentional performance. In fact, OxA sometimes further exacerbated
the adverse impact of MK-801. In neurological conditions wherein frontocortical
neurotransmission is substantially reduced, such as in Alzheimer’s, ADHD, or
Parkinson’s disease, OxA and other compounds agonizing these orexinreleasing neurons have been speculated to alleviate cognitive deficits by
bolstering the release of monoamines such as DA, ACh, and histamine
throughout pertinent cortical regions (Fadel, Pasumarthi & Reznikov, 2005; Vittoz
& Berridge, 2006). The present findings suggest that OxA, while having
previously been found to either boost cognition or alleviate related deficits in
following some forms of dysfunctional CNS activity, is not a viable
pharmacotherapy when attempting to treat the negative symptoms of SZ. Thus,
although OxA can still be considered a cognition-boosting agent, this beneficial
quality is not reflected across all disorders and may be, in large part, reliant on
dampened cholinergic neurotransmission (Zajo et al., 2016). With disorders such
as SZ, where cortical excitation is elevated, it appears that OxA has little or
possibly even a negative effect on attention and cognitive processing.
One potential shortcoming of this study is the effectiveness of the chosen
doses of MK-801. With 0 nM of OxA, while the high dose of 0.125 mg/kg had an
extremely profound impact in terms of both impairing accuracy and increasing
omissions in the attention task, the 0.075 mg/kg concentration failed to induce
deficits in both of those regards. Previous studies utilizing 0.1 mg/kg or higher
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have consistently provided findings similar to those generated by this
experiment in that many facets of cognition, such as attention, learning, and
working memory, are impaired; however, lower doses, such as 0.05 and 0.075
mg/kg, have offered mixed results in their cognition-impairing abilities (Hliňáka &
Krejčıb
́ , 2002; Howe & Burk, 2007; van der Staay et al., 2011). Therefore, it may
be that 0.075 mg/kg on its own was too low of a concentration to sufficiently
block NMDAR function to the extent that it would produce the full impairment in
attentional performance that is seen quite drastically with the 0.125 mg/kg dose.
While this may affect the interpretation of the current study in terms of its
applicability to emulating SZ symptomology, the elevated dose of intranasal OxA
still reduced attentional capacity, perhaps indicative of OxA’s tendency to further
worsen the effects of NMDAR inhibition in the cortex.
Future directions
If OxR activation worsens frontocortical hypexcitation induced by NMDAR
antagonism, it may be the case that reducing the input from these receptors
could enhance cognition in this and other conditions demonstrating similar
abnormalities in cortical excitatory neurotransmission. Drugs that target and
reduce the activation of Ox1Rs and Ox2Rs, for example, could temporarily
lessen the consequences of hyperfrontality and alleviate some of the cognitive
deficits seen in SZ and similar disorders. Preliminary findings from our lab have
shown that, at small concentrations, the Ox2R antagonist TCS-OX2-29 is able to
transiently improve performance in the sustained attention task in neurotypical
rats when infused directly into the medial PFC (Tapp, Maness, & Burk, in
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preparation). These findings, taken with the results from the present experiment,
provide an impetus to explore the implications of Ox1R or Ox2R blockade on
attentional and cognitive performance in a similar NMDAR hypofunction model of
SZ. Additionally, the orexin system is critical for sleep and circadian rhythmicity,
so the suppression of these neurons may have unforeseen impacts on sleep
quality and drowsiness that may assuage its beneficial effects on cognitive
performance.
Because the cognition-boosting qualities of OxA are worth further
elucidation in the context of intranasal administration due to ease of selfadministration and how quickly it elicits its effects, it may be useful to examine its
therapeutic effects following widespread loss of cholinergic neurons. The
tendency for OxA to worsen measures of accuracy in the attention task in rats
treated with MK-801, particularly with correct rejections, indicates that OxA may
be exerting much of its influence on basal forebrain cholinergic inputs to the
cortex and subcortex. One method that could verify this synergistic orexinergiccholinergic interaction, similarly to a study by Zajo, Fadel and Burk (2016)
wherein intracerebroventricular infusions of OxA were able to alleviate attentional
deficits following basal forebrain corticopetal lesions, would involve disrupting
BFCS functionality – either with a cholinergic antagonist or the cholinergic
immunotoxin 192 IgG-saporin – and administering OxA intranasally preceding
placement in the operant task. In doing so, the influence of lateral hypothalamic
orexinergic efferents on the basal forebrain would be better understood, and the
therapeutic potential of nasal OxA administration would be further established in
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the context of Alzheimer’s and Parkinson’s diseases, wherein cholinergic
neurotransmission is compromised.
Conclusion
In an MK-801 model of SZ, increased activation of orexin receptors
through the introduction of intranasal OxA did not alleviate MK-801-induced
attentional deficits. This failure of OxR stimulation to enhance cognition in this
paradigm is likely due to its tendency to worsen the cognitive and perhaps
perceptual disturbances resulting from a failure of NMDAR and GABAR
regulation of excitatory neurotransmitter release in the PFC and other cortical
regions. Additionally, because of orexinergic innervation onto basal forebrain
cholinergic neurons, hypercholinergia was likely aggravated after OxA exposure,
failing to improve measures of attentional accuracy. These findings further
discern the role of this neuropeptide as a “cognition-enhancer” in certain
circumstances and not others, and they also suggest that alleviating the
abnormal cognition and behaviors seen in SZ may lie in the reduction, rather
than promotion, of frontal lobe stimulation. In this regard, Ox1R and/or Ox2R
antagonists may provide a unique advantage in this model by assuaging cortical
hyperexcitation. In a similar vein, further attempts to explore the potential for
drugs that strengthen OxR activity as a form of pharmacotherapy to treat
disorders with a cognitive component would likely yield more successful results in
the framework of dampened cortical excitation. In particular, cognitive decline
stemming from loss of cholinergic fibers, which occurs during neurodegeneration
and is especially aggravated in dementing states, may benefit from intranasal
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OxA administration. Therefore, while not advantageous in a rodent model of SZ,
OxA can still be classified as a cognition-boosting agent in the appropriate
neurological context.
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Appendix

Figure 1. Hit percentages at each dose of OxA (0, 5, and 10 nM) across the three
concentrations of MK-801 (0, 0.075, and 0.125 mg/kg). MK-801 impaired overall
performance on this measure at 0.125 mg/kg, but not at 0.075 mg/kg. While
there was a significant interaction between MK801, OxA, and signal duration
when excluding the largest MK-801 dose, there were no differences in signal
detection accuracy between the three OxA concentrations at 0 and 0.075 mg/kg.
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Figure 2. Hit percentages at each signal duration (500, 100, and 25 ms) at the
three doses of OxA averaged across MK-801 concentration. There was a
statistically significant interaction between OxA and signal duration, which was
further examined in figure 3.
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Figure 3. Hit percentages at each signal duration (500, 100, and 25 ms) at 0
mg/kg and 0.075 mg/kg of MK-801 following intranasal saline administration.
There was a statistically significant interaction between MK-801 and signal
duration. Despite this, there were no substantial changes in signal detection
accuracy within the three signal durations from saline injections to the low dose
of MK-801.
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Figure 4. Correct rejection percentages at each of the three OxA doses across
the three concentrations of MK-801.Similarly to relative hits, MK-801 impaired
overall performance on this measure at 0.125 mg/kg, but not at 0.075 mg/kg. At 0
mg/kg of MK-801, the identification of non-signal trials following 5 nM of OxA was
impaired when compared to performance at 10 nM. From 0 mg/kg to 0.075
mg/kg, correct rejections after exposure to 10 nM of OxA decreased while 5 nM
prevented a significant impairment in performance. At 0.075 mg/kg of MK-801,
correct rejection accuracy at 5 nM of OxA was enhanced when compared to 10
nM.
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Figure 5. Omission rates at each of the three OxA doses across the three
concentrations of MK-801. As the dose of MK-801 was augmented, trial
omissions dose-dependently increased despite OxA administration. While
omissions for 0 nM and 10 nM of OxA were elevated from 0 to 0.075 mg/kg of
MK-801, 5 nM of OxA protected against this significant increase, but trial
omissions increased dramatically following 0.125 mg/kg regardless of OxA dose.
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Figure 6. Omission rates following administration of 0, 5, and 10 nM of OxA
averaged across MK-801 concentration. When considering trial omissions, the
main effect of OxA approached significance, and follow up tests revealed that
rats almost omitted less after 5 nM of OxA than both saline and 10 nM.
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